Raymond James Begins Coverage on Gritstone Oncology (GRTS)

Share on StockTwits

Raymond James started coverage on shares of Gritstone Oncology (NASDAQ:GRTS) in a research report released on Thursday, MarketBeat.com reports. The brokerage issued an outperform rating and a $20.00 price objective on the stock.

A number of other brokerages have also commented on GRTS. HC Wainwright initiated coverage on shares of Gritstone Oncology in a research report on Thursday, March 7th. They set a buy rating and a $17.00 price objective for the company. BTIG Research upped their price objective on shares of Gritstone Oncology to $31.00 and gave the company a buy rating in a research report on Tuesday, December 11th. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the stock. The company presently has an average rating of Buy and a consensus target price of $22.20.

Shares of GRTS opened at $10.15 on Thursday. Gritstone Oncology has a 52 week low of $9.66 and a 52 week high of $32.90.

Institutional investors and hedge funds have recently made changes to their positions in the company. Svennilson Peter bought a new stake in Gritstone Oncology in the fourth quarter valued at about $47,940,000. Redmile Group LLC bought a new stake in Gritstone Oncology in the third quarter valued at about $31,935,000. FMR LLC bought a new stake in Gritstone Oncology in the third quarter valued at about $23,496,000. Partner Fund Management L.P. bought a new stake in Gritstone Oncology in the third quarter valued at about $14,257,000. Finally, BlackRock Inc. bought a new stake in Gritstone Oncology in the fourth quarter valued at about $6,182,000. 59.28% of the stock is owned by institutional investors and hedge funds.

About Gritstone Oncology

Gritstone Oncology Inc is engaged in the discovery and development of cancer immunotherapies. The company focuses on developing tumor-specific neo-antigens-based therapies for non-small cell lung cancer. Gritstone Oncology Inc has a strategic collaboration with bluebird bio, Inc The company was incorporated in 2015 and is based in San Francisco, California with operations in Cambridge, Massachusetts.

Recommended Story: What causes a recession?

Analyst Recommendations for Gritstone Oncology (NASDAQ:GRTS)

Receive News & Ratings for Gritstone Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gritstone Oncology and related companies with MarketBeat.com's FREE daily email newsletter.